Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.73 |
| ▸ | SELL | P14151 | 1/20 | 0.73 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.62 |
| ▸ | SELE | P16581 | 5/20 | 0.61 |
| ▸ | MAG | P20916 | 6/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29372449 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29405702 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL13978771 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29389517 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29448496 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29391699 | 1.00 | SELP (0.73) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29407985 | 0.99 | SELP (0.71) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29466129 | 0.98 | SELP (0.70) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL29466139 | 0.98 | SELP (0.70) | SELPSELLSIGLEC7SELEMAG | |
| SCHEMBL31010809 | 0.96 | SELP (0.71) | SELPSELLSIGLEC7SELEMAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240219402-A1 | METHODS FOR THE DETERMINATION OF THE PREDISPOSITION FOR A SEVERE OR CRITICAL COURSE OF A COVID-19-DISEASE FROM A MILD OR MODERATE COURSE OF A COVID-19-DISEASE IN A SUBJECT | SCIOMICS GMBH (DE) | 2024-07-04 | — | — | US | disclosed |
| US-20160067357-A1 | DETECTION OF HIGH RISK DRUSEN | APELLIS PHARMACEUTICALS, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160067357-A1 | DETECTION OF HIGH RISK DRUSEN | APELLIS PHARMACEUTICALS, INC. | 2016-03-10 | — | — | US | disclosed |
| WO-2014028861-A1 | DETECTION OF HIGH RISK DRUSEN | APELLIS PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-20110229409-A1 | LINKABLE LEWIS X ANALOGS | BRACCO INTERNATIONAL B.V. (NL) | 2011-09-22 | — | — | US | disclosed |
| US-7422733-B2 | Linkable sialyl Lewis X analogs | BRACCO INTERNATIONAL B.V. (NL) | 2008-09-09 | — | — | US | disclosed |
| US-7422733-B2 | Linkable sialyl Lewis X analogs | BRACCO INTERNATIONAL B.V. (NL) | 2008-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067357-A1 | DETECTION OF HIGH RISK DRUSEN | IL17A, EXOSC4, CFB | SELP 197/4885SELL 482/4885SIGLEC7 91/4885 |
| US-20110229409-A1 | LINKABLE LEWIS X ANALOGS | SELPLG, SELL, SELE | SELP 4/4885SELL 2/4885SIGLEC7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.